The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

amunix.com

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$190M

Valuation

$0000 

About Amunix

Amunix is focused on the discovery and development of long-acting protein-based therapeutics. Amunix's pipeline products are based on its proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate and ProTIA pro-drug, bispecific T-cell engager platform technologies. Amunix is applying these technologies over a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing. The company is actively engaged in both a diverse array of internal product development efforts as well as ongoing collaborations with leading biotechnology and pharma companies.On December 21st, 2021, Amunix was acquired by Sanofi at a valuation of $1B.

Amunix Headquarter Location

2 Tower Pl #1100

South San Francisco, California, 94080,

United States

650-428-1800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Amunix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Amunix is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

838 items

Amunix Patents

Amunix has filed 48 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Clusters of differentiation
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/2/2018

3/30/2021

Protein domains, Proteins, Molecular biology, Protein families, Biotechnology

Grant

Application Date

2/2/2018

Grant Date

3/30/2021

Title

Related Topics

Protein domains, Proteins, Molecular biology, Protein families, Biotechnology

Status

Grant

Latest Amunix News

RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

Apr 25, 2022

April 25, 2022 08:00 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. “RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to development treatment solutions for unmet medical need in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the RayzeBio board and management team to support the Company in its ambitious goals,” said Dr. You. “I am delighted to welcome Angie to our board of directors. We have worked together in previous organizations and my admiration for Angie’s talent and diverse skill set has only grown over time. She will be an invaluable resource to RayzeBio as we continue to expand the horizons of the targeted radiopharmaceuticals modality,” said Ken Song, M.D., President and CEO of RayzeBio. Dr. You joined Amunix Pharmaceuticals as CEO in 2018. Prior to joining Amunix, Dr. You served as chief business & strategy officer and head of commercial at Sierra Oncology (Nasdaq: SRRA), where she led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra Oncology, Dr. You served as CBO of Aragon Pharmaceuticals. In previous roles, Dr. You served as CBO at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College. About RayzeBio RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com Contacts

Amunix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Amunix Rank

  • When was Amunix founded?

    Amunix was founded in 2006.

  • Where is Amunix's headquarters?

    Amunix's headquarters is located at 2 Tower Pl, South San Francisco.

  • What is Amunix's latest funding round?

    Amunix's latest funding round is Acquired.

  • How much did Amunix raise?

    Amunix raised a total of $190M.

  • Who are the investors of Amunix?

    Investors of Amunix include vSpring Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.